澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 10.36 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium carbonate; purified talc; povidone; methionine; microcrystalline cellulose; crospovidone; mannitol; titanium dioxide; hypromellose; macrogol 6000 - an adjunct to diet for the treatment of patients with hypercholesterolaemia. . prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. . atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

加拿大 - 英文 - Health Canada

pharmascience inc - atorvastatin (atorvastatin calcium) - tablet - 10mg - atorvastatin (atorvastatin calcium) 10mg - hmg-coa reductase inhibitors

加拿大 - 英文 - Health Canada

pharmascience inc - atorvastatin (atorvastatin calcium) - tablet - 20mg - atorvastatin (atorvastatin calcium) 20mg - hmg-coa reductase inhibitors

加拿大 - 英文 - Health Canada

pharmascience inc - atorvastatin (atorvastatin calcium) - tablet - 40mg - atorvastatin (atorvastatin calcium) 40mg - hmg-coa reductase inhibitors

加拿大 - 英文 - Health Canada

pharmascience inc - atorvastatin (atorvastatin calcium) - tablet - 80mg - atorvastatin (atorvastatin calcium) 80mg - hmg-coa reductase inhibitors

加拿大 - 英文 - Health Canada

mylan pharmaceuticals ulc - atorvastatin (atorvastatin calcium) - tablet - 10mg - atorvastatin (atorvastatin calcium) 10mg - hmg-coa reductase inhibitors

加拿大 - 英文 - Health Canada

mylan pharmaceuticals ulc - atorvastatin (atorvastatin calcium) - tablet - 20mg - atorvastatin (atorvastatin calcium) 20mg - hmg-coa reductase inhibitors

加拿大 - 英文 - Health Canada

mylan pharmaceuticals ulc - atorvastatin (atorvastatin calcium) - tablet - 40mg - atorvastatin (atorvastatin calcium) 40mg - hmg-coa reductase inhibitors

加拿大 - 英文 - Health Canada

mylan pharmaceuticals ulc - atorvastatin (atorvastatin calcium) - tablet - 80mg - atorvastatin (atorvastatin calcium) 80mg - hmg-coa reductase inhibitors

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - ezetimibe, quantity: 10 mg; atorvastatin calcium trihydrate, quantity: 43.4 mg (equivalent: atorvastatin, qty 40 mg) - tablet, multilayer - excipient ingredients: hyprolose; lactose monohydrate; croscarmellose sodium; silicon dioxide; magnesium stearate; microcrystalline cellulose; povidone; polysorbate 80; sodium lauryl sulfate; calcium carbonate; titanium dioxide; macrogol 8000; hypromellose; purified talc - prevention of cardiovascular disease atozet is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of atorvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see clinical trials). primary hypercholesterolaemia atozet is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients: - not appropriately controlled with atorvastatin or ezetimibe alone; - or already treated with atorvastatin and ezetimibe homozygous familial hypercholesterolaemia (hofh) atozet is indicated in patients with hofh. patients may also receive adjunctive treatments (e.g. ldl apheresis).